These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31081451)

  • 1. Predictors of treatment outcome in patients with paediatric onset multiple sclerosis.
    Kopp TI; Blinkenberg M; Chalmer TA; Petersen T; Ravnborg MH; Soelberg Sørensen P; Magyari M
    Mult Scler; 2020 Jul; 26(8):964-975. PubMed ID: 31081451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.
    Kister I; Spelman T; Patti F; Duquette P; Trojano M; Izquierdo G; Lugaresi A; Grammond P; Sola P; Ferraro D; Grand'Maison F; Alroughani R; Terzi M; Boz C; Hupperts R; Lechner-Scott J; Kappos L; Pucci E; Hodgkinson S; Solaro C; Butzkueven H
    J Neurol Sci; 2018 Aug; 391():72-76. PubMed ID: 30103975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab treatment for multiple sclerosis in Austria: An observational long-term outcome study.
    Moser T; Foettinger F; Hitzl W; Novotna B; Berger T; Bsteh G; Di Pauli F; Hegen H; Kornek B; Langenscheidt D; Sellner J
    Ann Clin Transl Neurol; 2024 Jun; 11(6):1442-1455. PubMed ID: 38715245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse recovery: The forgotten variable in multiple sclerosis clinical trials.
    Kantarci OH; Zeydan B; Atkinson EJ; Conway BL; Castrillo-Viguera C; Rodriguez M
    Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 31848231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
    Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
    Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries.
    Hrnciarova T; Drahota J; Spelman T; Hillert J; Lycke J; Kubala Havrdova E; Recmanova E; Adamkova J; Mares J; Libertinova J; Pavelek Z; Hradilek P; Ampapa R; Stetkarova I; Peterka M; Martinkova A; Stourac P; Grunermelova M; Vachova M; Dufek M; Horakova D
    Mult Scler Relat Disord; 2023 Aug; 76():104803. PubMed ID: 37329786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics and use of disease modifying therapy in the nationwide Danish cohort of paediatric onset multiple sclerosis.
    Erdal JL; Kopp TI; Blinkenberg M; Petersen T; Sørensen PS; Magyari M
    Mult Scler Relat Disord; 2020 Jan; 37():101431. PubMed ID: 31670210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.
    Spelman T; Magyari M; Piehl F; Svenningsson A; Rasmussen PV; Kant M; Sellebjerg F; Joensen H; Hillert J; Lycke J
    JAMA Neurol; 2021 Oct; 78(10):1197-1204. PubMed ID: 34398221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.
    Baroncini D; Simone M; Iaffaldano P; Brescia Morra V; Lanzillo R; Filippi M; Romeo M; Patti F; Chisari CG; Cocco E; Fenu G; Salemi G; Ragonese P; Inglese M; Cellerino M; Margari L; Comi G; Zaffaroni M; Ghezzi A;
    JAMA Neurol; 2021 Jun; 78(6):726-735. PubMed ID: 33938921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal and spatial patterns in the prescriptions of disease-modifying therapies for multiple sclerosis. Results from the Italian Multiple Sclerosis and Related Disorders Register.
    Lepore V; Paletta P; Bosetti C; Santucci C; Ponzio M; Pupillo E; Leone MA; Bergamaschi R; Mosconi P;
    Mult Scler Relat Disord; 2024 Jul; 87():105638. PubMed ID: 38713966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early versus later treatment start in multiple sclerosis: a register-based cohort study.
    Chalmer TA; Baggesen LM; Nørgaard M; Koch-Henriksen N; Magyari M; Sorensen PS;
    Eur J Neurol; 2018 Oct; 25(10):1262-e110. PubMed ID: 29847005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed initiation of disease modifying therapy increases relapse frequency and motor disability in pediatric onset multiple sclerosis.
    Jafarpour S; Pinto S; Vu MH; Khoshnood MM; Ahsan N; Saucier LE; Santoro JD
    Mult Scler Relat Disord; 2024 Jul; 87():105669. PubMed ID: 38749351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis.
    Healy BC; Engler D; Gholipour T; Weiner H; Bakshi R; Chitnis T
    J Neurol Sci; 2011 Apr; 303(1-2):109-13. PubMed ID: 21251671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression.
    Salavisa M; Serrazina F; Ladeira AF; Correia AS
    Clin Neurol Neurosurg; 2023 Feb; 225():107612. PubMed ID: 36701940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
    Mouresan EF; Mentesidou E; Berglund A; McKay KA; Hillert J; Iacobaeus E
    Neurology; 2024 Mar; 102(6):e208051. PubMed ID: 38394472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparities in DMT treatment: Demographic and neurocognitive differences between MS patients currently treated versus not treated with disease-modifying therapies.
    Leavitt VM; Dworkin JD; Galioto R; Ratzan AS
    Mult Scler Relat Disord; 2024 May; 85():105508. PubMed ID: 38452646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.
    Chalmer TA; Kalincik T; Laursen B; Sorensen PS; Magyari M;
    J Neurol; 2019 Feb; 266(2):306-315. PubMed ID: 30515628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What an adult multiple sclerosis registry can tell us about pediatric onset multiple sclerosis?
    Alkolfat F; Said S; Mekky J; Eldeeb H
    Mult Scler Relat Disord; 2023 Nov; 79():104962. PubMed ID: 37714097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.